Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.48 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479161 | 0.85 | ITGB3 (0.43) | ITGB3ITGA2BACEECE1KIFC1 | |
| SCHEMBL4479163 | 0.85 | ITGB3 (0.43) | ITGB3ITGA2BACEECE1KIFC1 | |
| SCHEMBL3314974 | 0.83 | KIFC1 (0.37) | ACEECE1KIFC1 | |
| SCHEMBL3311174 | 0.75 | ADRB2 (0.43) | — | |
| SCHEMBL987963 | 0.75 | FAAH (0.64) | ITGB3ITGA2BACEFAAHCHRNB2 | |
| SCHEMBL265066 | 0.75 | FAAH (0.64) | ITGB3ITGA2BACEFAAHCHRNB2 | |
| SCHEMBL11793269 | 0.75 | FAAH (0.64) | ITGB3ITGA2BACEFAAHCHRNB2 | |
| SCHEMBL3310634 | 0.73 | TACR1 (0.44) | — | |
| SCHEMBL3316803 | 0.73 | TACR1 (0.44) | — | |
| SCHEMBL3309182 | 0.73 | ACE (0.49) | ITGB3ITGA2BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ITGB3 3048/4885ITGA2B 3269/4885ACE 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.